Lack of KRAS and BRAF Mutation in Renal Cell Carcinoma

Saved in:
Bibliographic Details
Published inEuropean urology Vol. 55; no. 6; pp. 1490 - 1491
Main Authors Gattenlöhner, S, Etschmann, B, Riedmiller, H, Müller-Hermelink, H.-K
Format Journal Article
LanguageEnglish
Published Switzerland Elsevier B.V 01.06.2009
Subjects
Antibodies, Monoclonal - therapeutic use
Biopsy, Needle
Carcinoma, Renal Cell - drug therapy
Carcinoma, Renal Cell - genetics
Carcinoma, Renal Cell - pathology
Cohort Studies
DNA Mutational Analysis
Female
Follow-Up Studies
Gene Expression Regulation, Neoplastic
Genes, ras - drug effects
Genes, ras - genetics
Humans
Immunohistochemistry
Kidney Neoplasms - drug therapy
Kidney Neoplasms - genetics
Kidney Neoplasms - pathology
Male
Mutation
Polymerase Chain Reaction
Proto-Oncogene Proteins B-raf - drug effects
Proto-Oncogene Proteins B-raf - genetics
Receptor, Epidermal Growth Factor - therapeutic use
Risk Assessment
Sensitivity and Specificity
Urology
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
ObjectType-Article-2
content type line 63
ObjectType-Correspondence-1
ISSN:0302-2838
1873-7560
DOI:10.1016/j.eururo.2009.02.024